| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 2931 | 2017 |
| Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled … H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ... Journal of clinical oncology 36 (7), 633, 2018 | 1232 | 2018 |
| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 801 | 2018 |
| Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes CC Coombs, A Zehir, SM Devlin, A Kishtagari, A Syed, P Jonsson, ... Cell stem cell 21 (3), 374-382. e4, 2017 | 673 | 2017 |
| Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ... Cancer discovery 7 (6), 596-609, 2017 | 574 | 2017 |
| Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade W Abida, ML Cheng, J Armenia, S Middha, KA Autio, HA Vargas, ... JAMA oncology 5 (4), 471-478, 2019 | 545 | 2019 |
| Genome doubling shapes the evolution and prognosis of advanced cancers CM Bielski, A Zehir, AV Penson, MTA Donoghue, W Chatila, J Armenia, ... Nature genetics 50 (8), 1189-1195, 2018 | 488 | 2018 |
| A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion–positive solid tumors A Drilon, R Nagasubramanian, JF Blake, N Ku, BB Tuch, K Ebata, S Smith, ... Cancer discovery 7 (9), 963-972, 2017 | 382 | 2017 |
| Tumour lineage shapes BRCA-mediated phenotypes P Jonsson, C Bandlamudi, ML Cheng, P Srinivasan, SS Chavan, ... Nature 571 (7766), 576-579, 2019 | 339 | 2019 |
| Genetic predictors of response to systemic therapy in esophagogastric cancer YY Janjigian, F Sanchez-Vega, P Jonsson, WK Chatila, JF Hechtman, ... Cancer discovery 8 (1), 49-58, 2018 | 316 | 2018 |
| Accelerating discovery of functional mutant alleles in cancer MT Chang, TS Bhattarai, AM Schram, CM Bielski, MTA Donoghue, ... Cancer discovery 8 (2), 174-183, 2018 | 309 | 2018 |
| Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance AM Schram, MT Chang, P Jonsson, A Drilon Nature reviews Clinical oncology 14 (12), 735-748, 2017 | 273 | 2017 |
| Insufficient antibody validation challenges oestrogen receptor beta research S Andersson, M Sundberg, N Pristovsek, A Ibrahim, P Jonsson, B Katona, ... Nature communications 8 (1), 15840, 2017 | 242 | 2017 |
| Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3 P Dey, P Jonsson, J Hartman, C Williams, A Ström, JÅ Gustafsson Molecular endocrinology 26 (12), 1991-2003, 2012 | 145 | 2012 |
| Estrogen receptor β induces antiinflammatory and antitumorigenic networks in colon cancer cells K Edvardsson, A Ström, P Jonsson, JÅ Gustafsson, C Williams Molecular endocrinology 25 (6), 969-979, 2011 | 140 | 2011 |
| Genome-wide profiling of AP-1–regulated transcription provides insights into the invasiveness of triple-negative breast cancer C Zhao, Y Qiao, P Jonsson, J Wang, L Xu, P Rouhi, I Sinha, Y Cao, ... Cancer research 74 (14), 3983-3994, 2014 | 135 | 2014 |
| Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab AL Lin, P Jonsson, V Tabar, TJ Yang, J Cuaron, K Beal, M Cohen, ... The Journal of Clinical Endocrinology & Metabolism 103 (10), 3925-3930, 2018 | 125 | 2018 |
| Genomic correlates of disease progression and treatment response in prospectively characterized gliomas P Jonsson, AL Lin, RJ Young, NM DiStefano, DM Hyman, BT Li, ... Clinical Cancer Research 25 (18), 5537-5547, 2019 | 123 | 2019 |
| AP-1 is a key regulator of proinflammatory cytokine TNFα-mediated triple-negative breast cancer progression Y Qiao, H He, P Jonsson, I Sinha, C Zhao, K Dahlman-Wright Journal of Biological Chemistry 291 (10), 5068-5079, 2016 | 120 | 2016 |
| miR-206 inhibits cell migration through direct targeting of the actin-binding protein Coronin 1C in triple-negative breast cancer J Wang, E Tsouko, P Jonsson, J Bergh, J Hartman, E Aydogdu, ... Molecular oncology 8 (8), 1690-1702, 2014 | 116 | 2014 |
